Anhui Huaheng Biotechnology Co., Ltd. (SHA:688639)
China
· Delayed Price · Currency is CNY 28.23
+0.71 (2.58%)
Apr 29, 2026, 3:00 PM CST
SHA:688639 Revenue
Anhui Huaheng Biotechnology had revenue of 771.26M CNY in the quarter ending March 31, 2026, with 12.26% growth. This brings the company's revenue in the last twelve months to 2.95B, up 24.61% year-over-year. In the year 2025, Anhui Huaheng Biotechnology had annual revenue of 2.86B with 31.40% growth.
Revenue (ttm)
2.95B
Revenue Growth
+24.61%
P/S Ratio
2.39
Revenue / Employee
1.31M
Employees
2,252
Market Cap
7.04B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.86B | 683.90M | 31.40% |
| Dec 31, 2024 | 2.18B | 239.67M | 12.37% |
| Dec 31, 2023 | 1.94B | 519.62M | 36.63% |
| Dec 31, 2022 | 1.42B | 464.56M | 48.69% |
| Dec 31, 2021 | 954.10M | 466.85M | 95.81% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Shanghai OPM Biosciences | 354.91M |
| Wuhan Keqian Biology Co.,Ltd | 949.74M |
| Suzhou Fengbei Biotech Stock | 3.17B |
| Jiangsu Aidea Pharmaceutical Group | 719.17M |
| Chengdu Kanghua Biological Products | 1.20B |
| R&G PharmaStudies | 851.01M |
| Innovita Biological Technology | 422.03M |
| Xiangxue Pharmaceutical | 1.47B |